• Recruiting

NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Updated: Oct 20

NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

CD38-Targeted ImmunoPET of Myeloma miami ola landgren

NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma


Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.


Sponsor

Hoag Memorial Hospital Presbyterian

 

ClinicalTrials.gov Identifier: NCT04405167

ClinicalTrials.gov Identifier: NCT04814615

Official Title: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications

First Posted : March 24, 2021

Click here to see details on ClinicalTrials.gov

 

Drug: 89Zr-daratumumab PET/CT

 

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | University of Miami Health System (umiamihealth.org)

 

Radiology. June 2020

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263286/

 

Location

- Florida: Sylvester Comprehensive Cancer Center - University of Miami

- United States, California



Posts Archive